Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
One-time use of CB-011, Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, showed a manageable safety profile and resulted in lasting responses in adults with…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
When it comes to medical jargon, where’s my secret decoder ring?
I see a lot of jargon in my line of work. A big part of my job is helping reporters translate it into something our…
Learning to reframe the stories we tell ourselves as caregivers
As a caregiver to my mum, who has myeloma, I usually experience some moments of quietness. One of these moments might be when we’re…
Myeloma treatment HDP-101 put on FDA fast track
The U.S. Food and Drug Administration (FDA) has granted fast track designation to HDP-101 (pamlectabart tismanitin), a multiple myeloma therapy currently in early clinical…
Navigating a myeloma diagnosis in the land of ‘I don’t know’
I am a longtime journalist with a firm belief that knowledge is power. My life’s work has been to answer the who, what, where, when,…
FDA approves Blenrep for relapsed or refractory multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved GSK‘s Blenrep (belantamab mafodotin) for adults with relapsed or refractory multiple myeloma. The approval…
